![]() |
|
|
Vol. 29, Issue 7, 1042-1050, July 2001
Institute of Toxicology, Merck KGaA, Darmstadt, Germany (N.J.H.,
D.U.); and Institute of Pharmacokinetics and Metabolism, Merck KGaA,
Grafing, Germany (K.-U.B., J.D., J.H., B.L.)
The in vivo metabolism of three pharmaceutical compounds,
EMD68843, EMD96785, and EMD128130, was compared in fresh and
cryopreserved hepatocyte (CPH) suspensions and microsomes from rat,
dog, monkey, and human livers and fresh human and rat hepatocyte
collagen gel immobilized cultures (GICs). Half of the major in vivo
metabolites was produced by phase 1 (hydroxylation, oxidation,
hydrolysis, N-dealkylation) and half by phase 2 metabolism (mostly glucuronidation but also sulfation and glycine
conjugation). The identity and percentage of phase 1 and 2 metabolites
from each compound produced in hepatocytes compared well with that in
each species in vivo. Glucuronidation was more extensive in GICs than
in CPHs. In contrast, CPHs but not GICs, produced sulfate metabolites.
Microsomes (supplemented with NADPH only) produced most of the phase 1 but no phase 2 metabolites. Metabolism in CPHs was the same as in fresh
hepatocyte suspensions. Discrete species differences in metabolism were
detected by CPHs and microsomes. Cytochrome P450 and glucuronosyl
S-transferase contents of CPHs did not account for
species differences in the percentage of phase 1 and 2 metabolites or
the rate of disappearance of the parent compounds in these cells. These
data show a good correlation between major metabolites formed in vivo
and in vitro. CPHs and GICs, unlike microsomes, carried out sequential
phase 1 and 2 metabolism. Each in vitro system has its own advantages, however, for short-term metabolism studies CPHs may be more useful since they are readily available, easier and quicker to prepare than
GICs, and have more comprehensive enzyme systems than microsomes.
This article has been cited by other articles:
![]() |
L. J. Christopher, D. Cui, W. Li, A. Barros Jr., V. K. Arora, H. Zhang, L. Wang, D. Zhang, J. A. Manning, K. He, et al. Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys Drug Metab. Dispos., July 1, 2008; 36(7): 1341 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. S. Poet, H. Wu, J. C. English, and R. A. Corley Metabolic Rate Constants for Hydroquinone in F344 Rat and Human Liver Isolated Hepatocytes: Application to a PBPK Model Toxicol. Sci., November 1, 2004; 82(1): 9 - 25. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. McGinnity, M. G. Soars, R. A. Urbanowicz, and R. J. Riley EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE Drug Metab. Dispos., November 1, 2004; 32(11): 1247 - 1253. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J Hewitt and D. Utesch Cryopreserved rat, dog and monkey hepatocytes: measurement of drug metabolizing enzymes in suspensions and cultures Human and Experimental Toxicology, June 1, 2004; 23(6): 307 - 316. [Abstract] [PDF] |
||||
![]() |
Y. Naritomi, S. Terashita, A. Kagayama, and Y. Sugiyama Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro Drug Metab. Dispos., May 1, 2003; 31(5): 580 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Graham, A. Downey, D. Mudra, L. Krueger, K. Carroll, C. Chengelis, A. Madan, and A. Parkinson In Vivo and in Vitro Induction of Cytochrome P450 Enzymes in Beagle Dogs Drug Metab. Dispos., November 1, 2002; 30(11): 1206 - 1213. [Abstract] [Full Text] [PDF] |
||||